Physician profile
Luis S Veras
NPI 1215013560
$929.26
in general payments reported to CMS, 2019-2025
18 companies · $79.50 in 2025
The $79.50 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2021: $18.24 · 2022: $21.99 · 2023: $105 · 2025: $79.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.50 | 2019 | |
| Glaxosmithkline, LLC. | $142.17 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.42 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $81.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.42 | 2019-2021 | |
| Lilly USA, LLC | $49.45 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $48.64 | 2019 | |
| Exact Sciences Corporation | $45.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $39.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.46 | 2019 | |
| Merck Sharp & Dohme LLC | $21.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.85 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.16 | 2019 | |
| Allergan, INC. | $15.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Veras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.